James F. Young Sells 7,500 Shares of Novavax, Inc. (NASDAQ:NVAX) Stock

Novavax, Inc. (NASDAQ:NVAX) Director James F. Young sold 7,500 shares of the stock in a transaction on Tuesday, June 18th. The shares were sold at an average price of $13.72, for a total value of $102,900.00. Following the transaction, the director now directly owns 69,260 shares of the company’s stock, valued at $950,247.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Novavax Trading Down 0.1 %

Shares of NVAX opened at $14.00 on Wednesday. The firm has a market cap of $1.97 billion, a PE ratio of -4.42 and a beta of 1.94. The firm has a fifty day simple moving average of $11.44 and a two-hundred day simple moving average of $7.06. Novavax, Inc. has a 1-year low of $3.53 and a 1-year high of $23.86.

Novavax (NASDAQ:NVAX) last posted its quarterly earnings data on Friday, May 10th. The biopharmaceutical company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($1.04) by ($0.01). The firm had revenue of $93.90 million during the quarter, compared to analysts’ expectations of $71.32 million. Novavax’s quarterly revenue was up 15.9% compared to the same quarter last year. During the same period last year, the business earned ($3.41) EPS. As a group, research analysts forecast that Novavax, Inc. will post 0.49 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have issued reports on the company. JPMorgan Chase & Co. upgraded Novavax from an “underweight” rating to a “neutral” rating in a research report on Friday, May 10th. HC Wainwright restated a “buy” rating and set a $19.00 target price on shares of Novavax in a research report on Monday, May 13th. TD Cowen increased their target price on Novavax from $5.00 to $10.00 and gave the stock a “hold” rating in a research report on Monday, May 13th. Bank of America increased their target price on Novavax from $12.00 to $18.00 and gave the stock a “neutral” rating in a research report on Friday, June 14th. Finally, B. Riley increased their price objective on Novavax from $11.00 to $29.00 and gave the stock a “buy” rating in a research report on Thursday, May 23rd. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, Novavax has an average rating of “Hold” and an average price target of $19.00.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in NVAX. Coatue Management LLC bought a new position in shares of Novavax during the 4th quarter valued at about $7,294,000. Shah Capital Management lifted its holdings in shares of Novavax by 22.9% in the 4th quarter. Shah Capital Management now owns 7,780,756 shares of the biopharmaceutical company’s stock valued at $37,348,000 after acquiring an additional 1,450,000 shares during the last quarter. Farallon Capital Management LLC bought a new stake in Novavax in the first quarter worth about $5,406,000. Vanguard Group Inc. lifted its stake in Novavax by 9.3% in the third quarter. Vanguard Group Inc. now owns 11,551,476 shares of the biopharmaceutical company’s stock worth $83,633,000 after purchasing an additional 978,873 shares during the last quarter. Finally, Rafferty Asset Management LLC lifted its stake in Novavax by 62.4% in the fourth quarter. Rafferty Asset Management LLC now owns 1,611,840 shares of the biopharmaceutical company’s stock worth $7,737,000 after purchasing an additional 619,370 shares during the last quarter. Institutional investors own 53.04% of the company’s stock.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.